For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Participants 10 to <11 Years of Age | Participants received 1 dose of Adacel® vaccine at Visit 1. | None | None | 0 | 651 | 521 | 651 | View |
| Participants 11 to <12 Years of Age | Participants received 1 dose of Adacel® vaccine at Visit 1. | None | None | 1 | 651 | 522 | 651 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Cerebrovascular accident | NON_SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 13.0 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Injection-site Pain | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 13.0 | View |
| Injection-site Erythema | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 13.0 | View |
| Injection-site Swelling | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 13.0 | View |
| Headache | SYSTEMATIC_ASSESSMENT | Nervous system disorders | MedDRA 13.0 | View |
| Malaise | SYSTEMATIC_ASSESSMENT | General disorders | MedDRA 13.0 | View |
| Myalgia | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | MedDRA 13.0 | View |